
The FLEX study enhances breast cancer treatment by integrating genomic data, guiding therapy choices, and improving patient outcomes.

The FLEX study enhances breast cancer treatment by integrating genomic data, guiding therapy choices, and improving patient outcomes.

New findings at SABCS reveal MammaPrint's role in identifying early-stage breast cancer patients who benefit from anthracyclines, reducing unnecessary treatment.